Modellbasierte Identifikation fraktionaler Systeme und ihre Anwendung auf die Lithium-Ionen-Zelle

In dieser Arbeit werden modellbasierte Verfahren zur Online-Identifikation physikalischer Alterungsparameter von Batteriezellen entworfen und auf die Lithium-Ionen-Zelle angewendet. Die neuartigen Methoden basieren auf fraktionalen Impedanzmodellen und agieren, im Unterschied zum State-of-the-Art, erstmals als late-lumping Verfahren. Zudem wird in diesem Beitrag die zeitvariante fraktionale Systemtheorie um eine Steuerbarkeitsanalyse und eine energieoptimale Steuerung erweitert

Fractional Systems’ Identification Based on Implicit Modulating Functions

This paper presents a new method for parameter identification based on the modulating function method for commensurable fractional-order models. The novelty of the method lies in the automatic determination of a specific modulating function by controlling a model-based auxiliary system, instead of applying and parameterizing a generic modulating function. The input signal of the model-based auxiliary system used to determine the modulating function is designed such that a separate identification of each individual parameter of the fractional-order model is enabled. This eliminates the shortcomings of the common modulating function method in which a modulating function must be adapted to the investigated system heuristically

Automatic Determining of a Modulating Function

This article shows how modulating functions can be generated automatically and used to identify selected parameters of commensurable fractional systems. Existing methods use universal modulating functions. These have to be adjusted to each single problem. The proposed method uses a model based auxiliary system which is derived from the actual system, but has a fixed structure. The problem of applying a suitable modulating function is transformed into a control problem. Taking an additional precondition into account, each parameter can be separately identified. A study of the practical applicability and a numerical example complete the article

Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis : analysis of pooled data from the randomized trials SOLO 1 and SOLO 2

Background: Atopic dermatitis (AD) profoundly affects quality of life (QoL). Dupilumab significantly improves clinical outcomes, is well tolerated, and approved to treat inadequately controlled moderate-to-severe AD in adults; however, its effect on patient-reported outcomes (PROs) is not fully characterized. Objective: To evaluate the impact of dupilumab on patient-reported AD symptoms and QoL. Methods: Pooled data were analyzed from two identically designed phase 3 studies, LIBERTY AD SOLO 1 (NCT02277743) and SOLO 2 (NCT02277769), assessing the following PROs: Peak Pruritus Numerical Rating Scale (NRS), Pruritus Categorical Scale, SCORing AD (SCORAD), Dermatology Life Quality Index (DLQI), Patient-Oriented Eczema Measure (POEM), Hospital Anxiety and Depression Scale (HADS), five-dimension EuroQoL questionnaire (EQ-5D), and patient-assessed disease status and treatment effectiveness. Results: Dupilumab rapidly improved (vs. placebo) Peak Pruritus NRS scores by day 2 (p <.05), anxiety and depression (HADS), and QoL (DLQI) by week 2, and maintained through week 16 (p <.0001). At week 16, more dupilumab-treated than placebo-treated patients reported improvement in SCORAD itch and sleep, and no pain/discomfort (EQ-5D) (p <.0001). Limitations: Cultural differences of translated PROs. Conclusion: Dupilumab had a significant, positive impact on AD symptoms, including itch, sleep, pain, anxiety and depression, and QoL in adults with moderate-to-severe AD.Peer reviewe

The fusion approach – applications for understanding local government and European integration

The article explores the theoretical capabilities of the fusion approach as a conceptual ‘kit’ to explain the ‘bigger picture’ of European integration from a local government perspective. Fusion addresses the rationales and methods facilitating the transfer of policy-making competences to the European level. It understands European integration as a merging of public resources and policy instruments from multiple levels of government, whereby accountability and responsibilities for policy outcomes become blurred. The article argues that the fusion approach is useful to explain the systemic linkages between macro-trajectories and the corresponding change at the local level; the fusion dynamics of the local and European levels in a common policy-cycle; and the attitudes of local actors towards the EU. Although the article concludes that local government is rather modestly ‘fused’ into the EU, fusion approaches allow examining the extent to which the local level has become integrated into the European governance system

Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

BACKGROUND: Significant unmet need exists for long-term treatment of moderate to severe atopic dermatitis (AD). OBJECTIVE: To assess the long-term safety and efficacy of dupilumab in patients with AD. METHODS: This ongoing, multicenter, open-label extension study (NCT01949311) evaluated long-term dupilumab treatment in adults who had previously participated in phase 1 through 3 clinical trials of dupilumab for AD. This analysis examined patients given 300 mg dupilumab weekly for up to 76 weeks at data cutoff (April 2016). Safety was the primary outcome; efficacy was also evaluated. RESULTS: Of 1491 enrolled patients (1042.9 patient-years), 92.9% were receiving treatment at cutoff. The safety profile was consistent with previously reported trials (420.4 adverse events/100 patient-years and 8.5 serious adverse events/100 patient-years), with no new safety signals; common adverse events included nasopharyngitis, conjunctivitis, and injection-site reactions. Sustained improvement was seen up to 76 weeks in all efficacy outcomes, including measures of skin inflammation, pruritus, and quality of life. LIMITATIONS: Lack of control arm, limited number of patients with 76 weeks or longer of treatment (median follow-up, 24 weeks), and patients not receiving the approved dose regimen of 300 mg every 2 weeks. CONCLUSION: The safety and efficacy profile from this study supports the role of dupilumab as continuous long-term treatment for patients with moderate to severe AD

Modellbasierte Identifikation fraktionaler Systeme und ihre Anwendung auf die Lithium-Ionen-Zelle

In this work, model-based methods for the online identification of physically motivated aging parameters of battery cells are presented and applied to lithium-ion-cells. The new methods are based on fractional impedance models and, in contrast to the state of the art, are late-lumping approaches. A further contribution of this work is the extension of the theory of time-variant fractional systems by a controllability analysis and an energy-optimized control